Reimagining the Future of Rare Lung Disease Treatment

Corporate Overview

Nasdaq: AVLN

November 2026

TARGETED THERAPIES FOR RARE LUNG DISEASES

Disclaimer

This presentation includes forward looking statements, including statements related to our product candidates, preclinical and/or clinical trial timelines and projected data announcements, as well as statements related to patient populations and total addressable markets . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, strategy and plans, industry environment, potential growth opportunities, and our expectations for future operations, are forward looking statements The words " believe," " may," "will," "estimate," " continue," " anticipate," " design," " " expect," " could," " plan," " potential," " predict," " seek," " should," "would," or the negative version of these words and similar expressions are intended to identify forward looking statements. We have based these forward looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short and long term business operations and objectives, and financial needs. These forward looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward looking statements we may make In light of these risks, uncertainties and assumptions, the forward looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. You should not rely upon forward looking statements as predictions of future events. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward looking statements. We undertake no obligation to update publicly any forward looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. This presentation contains estimates and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, market research or similar methodologies, including prevalence studies which are extrapolated to broader populations, is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this presentation, this information could prove to be inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. While we are responsible for the accuracy of such information and believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.


Our Approach Reimagines the Future of Rare Lung Disease Treatment

- Clinical-stage portfolio of inhaled therapies targeting multi-billion dollar total addressable market
- Multiple clinical catalysts expected in 2026 and beyond
- Well-capitalized with $345M raised in upsized IPO (Nasdaq: AVLN) in April 2026, cash runway projected into 2029
- Expert team with deep experience developing & commercializing inhaled therapies


avalyn

Pulmonary Fibrosis: Deadly Disease with Limited Approved Agents

3-5 year survival rate – worse than most forms of cancer[1-4]



~70% of IPF patients are not on therapy[5]



~30% treated with oral medicines[8]

~50% discontinue[5-7], largely due to **poor tolerability**

[1]Nathan et al. 2011; [2]Zheng et al. 2022; [3]American Cancer Society. Cancer Facts and Figures 2018; [4]Benza RL et al. 2010; [5]Dempsey et al. 2021; [6]Belhassen et al., 2021; [7]Corral et al., 2020; [8]Avalyn Market Research

Inhaled Delivery Has Potential to Improve Efficacy and Tolerability of Approved Oral Agents

AVALYN'S TREATMENT APPROACH



Increases lung exposure
even at >10x lower dose than oral

+



Decreases systemic exposure

=



Dramatic improvement to existing product profiles

avalyn

Clinical Stage Portfolio with Potential to Transform Treatment of Pulmonary Fibrosis

AP01

Inhaled pirfenidone: Enrollment completed in global Phase 2b MIST study in PPF; data expected 2H27

- >150 patients with pulmonary fibrosis studied in Phase 1 and open label extension studies
  - Substantially better activity compared to historic oral data with potential for disease modification
  - Generally well-tolerated with fewer AEs vs historic oral pirfenidone
  - Originally targeting 375 patients, the Phase 2b study enrolled 398 patients due to high level of interest from investigators and patients

AP02

Inhaled nintedanib: Phase 2 global AURA study in IPF initiated; data expected late 2027

- Significantly higher lung exposure than orals demonstrated in Phase 1 trial
- Generally well-tolerated in Phase 1 with no bronchospasm or diarrhea observed

AP03

Inhaled pirfenidone + nintedanib fixed-dose combination: initiated Phase 1 in late 2026; data expected 2H27

- We believe combining mechanisms is only tolerable with inhaled delivery
- Healthy volunteer study of at least 32 participants with initial dosing at 50 mg pirfenidone + 2 mg nintedanib

AE, adverse event. MIST NCT06329401; AURA NCT07194382

We Believe Avalyn is Positioned to Evolve the Treatment Algorithm in PF

Asthma and COPD treatments now include many combinations


GENERATION 1 (1960s+)	GENERATION 2 (1990s+)	GENERATION 3 (2000s+)	GENERATION 4 (Today)
Oral Molecules	Inhaled Molecules	Dual FDCs	Triple FDCs
Prednisone Tablets USP; Theo-dur® Theophylline; Primatene®	FloVent Diskus; Pulmicort®; SereVent® Diskus®; SPIRIVA® RESPIMAT® (tiotropium bromide) INHALATION SPRAY	ADVAIR; BREO ELLIPTA; Symbicort®	TRELEGY ELLIPTA; BREZTRI AEROSPHERE®

Rapid evolution of PF treatment options

GENERATION 1 (2014 - Today)	GENERATION 2	GENERATION 3	GENERATION 4 (Future)
Oral Molecules	Inhaled Molecules	Dual FDCs	Triple FDCs
Esbriet® (pirfenidone) tablets; Jascayd® nerandomilast tablets; OFEV® nintedanib	avalyn pharma AP01; AP02	avalyn pharma AP03	avalyn pharma undisclosed

FDC: fixed dose combinations. All registered trademarks are the property of their respective owners.

IPF and PPF Are Two Key Types of Interstitial Lung Disease



>200 types[1] of interstitial lung diseases (ILDs)

ILD-associated inflammation can lead to fibrosis, damaging the lung's ability to absorb oxygen

- Idiopathic Pulmonary Fibrosis (IPF) is the **most well-known form of ILD**
- **Progressive Pulmonary Fibrosis (PPF) is a larger** and poorly served segment of the ILD market

[1]Jeganathan et al., 2024; [2]Avalyn Market Research; [3]Olson et al., 2021. PPF, previously referred to as Progressive Fibrosing ILD (PF-ILD)

avalyn

Pulmonary Fibrosis Represents a Large Market Opportunity in the US



>$4B
Ofev® global revenue in 2025

~$2B
Jascayd® annualized run rate

Ofev revenue from Boehringer Ingelheim, annual reports; Jascayd run rate based on IMS data. [1]Jeganathan et al., 2024; [2]Fan et al., 2024; [3]Singer et al., 2022. Ofev approved in SSc-ILD (2019) and PF-ILD (2020). All registered trademarks are the property of their respective owners.

avalyn

Avalyn's Anticipated Near-Term Value Inflection Points

Program	1H26	2H26	1H27	2H27	Anticipated Milestones
AP01 (Inhaled pirfenidone)	MIST Phase 2b Enrollment Completed			MIST Phase 2b Study Readout	✓ Ph2b trial enrollment completed mid 2026 • Ph2b top line data expected 2H27
AP02 (Inhaled nintedanib)	AURA Phase 2 Initiated			AURA Phase 2 Study Readout	✓ First patient dosed in Ph2 trial 1Q26 • Ph2 top line data expected late 2027
AP03 (Inhaled pirfenidone + nintedanib fixed-dose combination)		AP03 Phase 1 Initiated		AP03 Phase 1 Study Readout	✓ Ph1 trial initiated 4Q26 • Ph1 top line data expected 2H27

avalyn

Optimized Drug/Device Combination for Treatment of PF



- Handheld nebulized formulation delivered by proprietary, patented, 510(k) cleared PARI eFlow® device.
- Device would be included in FDA label. The same device configuration is used in other commercial products, including Insmed's Arikayce® and Gilead's Cayston®
- Avalyn has licensed device with exclusivity in molecules
- Administration averages less than 10 minutes, twice a day
- Aerosol particle size designed to achieve optimal deposition in peripheral airways and alveolus

All registered trademarks are the property of their respective owners.

AP01: Inhaled Pirfenidone

avalyn

Inhaled Pirfenidone (AP01): Phase 1b ATLAS Trial
Open-Label Extension (OLE) / AP01-Naïve Trials Include IPF and PPF

COMPLETED


ATLAS Trial in IPF Patients

- ✓ Study complete
- ✓ Data published in *Thorax* in March 2023[1]

ONGOING

Open-Label Extension (OLE) / AP01-Naïve IPF & PPF Trial


- All patients on 100 mg BID dose
- Initiated June 2021
- 4.5 years of lung function stabilization and tolerability data for roll-over patients announced May 2025
- Some patients from ATLAS on AP01 for 5+ years




*Last updated December 2025; [1]West, A. et al, (2023) *Thorax*

AP01 Showed Improved Tolerability in ATLAS

Top 10 AEs for Oral Pirfenidone (Esbriet®)



Corresponding AEs from AP01 (ATLAS study)



Pooled Historic Data[1]
Oral Placebo (n=624)
Oral Pirfenidone, 801mg TID (n=623)

AP01-002 ATLAS Trial[2]
AP01 (Inhaled Pirfenidone), 50mg QD (n=46)
AP01 (Inhaled Pirfenidone), 100mg BID (n=45)


- Gastrointestinal and skin AEs are common reasons for discontinuing oral pirfenidone


- Compared to the historic pooled data on oral pirfenidone, patients in the ATLAS trial were:
  - Older
  - Generally lower FVC
  - Longer time since diagnosis

These cross-study comparisons are provided for illustrative purposes only as there are no head-to-head comparison available. Comparing the results from different trials may be unreliable due to factors such as protocol design and trial objectives varying between the trials. Therefore, cross-study comparisons provide limited information about the effectiveness of a product candidate and should not be relied on.

[1]Pirfenidone (Esbriet®) Prescribing Information; [2]West et al., *Thorax* 2023
*Anorexia refers to decreased appetite; FVC = Forced vital capacity

AP01 100mg Achieved Near Stabilization in ATLAS Exhibiting Significant Dose-Dependent Improvement in Lung Function





These cross-study comparisons are provided for illustrative purposes only as there are no head-to-head comparison available. Comparing the results from different trials may be unreliable due to factors such as protocol design and trial objectives varying between the trials. Therefore, cross-study comparisons provide limited information about the effectiveness of a product candidate and should not be relied on.

*Through 48 weeks, 100 mg BID vs. 50 mg QD p=0.0222 (24-week p=0.133). Historic oral and AP01 data are non-imputed;
[1]West et al., *Thorax* 2023 [2]King et al., *N Engl J Med* 2014

avalyn

Oral Data Suggests Avalyn's Inhaled Pirfenidone (AP01) Achieves Favorable FVC Change

Avalyn AP01		Oral pirfenidone *(Esbriet®)*						Oral nintedanib *(Ofev®)*						Oral nerandomilast *(Jascayd®)*			
IPF	Indication	IPF		IPF		IPF		IPF		IPF		PPF		IPF		PPF	
ATLAS[1]	Trial	CAPACITY-1[2]		CAPACITY-2[2]		ASCEND[3]		INPULSIS-1[4]		INPULSIS-2[4]		INBUILD[5]		FIBRONEER[6]		FIBRONEER[7]	
-188	FVC decline 1 year *(mL)*	-350	-181	-274	-220	-265	-118	-240	-115	-207	-114	-188	-81	-149	-79	-154	-95
-34																	
50 mg QD	Arm	Placebo	801mg TID	Placebo	801mg TID	Placebo	801mg TID	Placebo	150mg BID	Placebo	150mg BID	Placebo	150mg BID	Placebo	18mg BID	Placebo	18mg BID
100 mg BID																	
46*	# of patients	174	174	173	171	277	278	204	309	219	329	331	332	87	87	222	220
42*																	


Average rate of decline in lung function due to aging is 20-50mL/year after age 40[8, 9]

These cross-study comparisons are provided for illustrative purposes only as there are no head-to-head comparison available. Comparing the results from different trials may be unreliable due to factors such as protocol design and trial objectives varying between the trials. Therefore, cross-study comparisons provide limited information about the effectiveness of a product candidate and should not be relied on.

[1]West et al., 2023; [2]Pirfenidone NDA – Medical Reviews; [3]Pirfenidone NDA – Statistical Reviews; [4]Richeldi et al., 2014; [5]Flaherty et al., 2019; [6]Richeldi et al., 2025; [7]Maher et al., 2025. [8]Torris et al., 2017; [9]Thomas et al., 2019; *Per protocol set in 48-week trial. ASCEND, INPULSIS, ATLAS, and INBUILD data are non-imputed. CAPACITY and FIBRONEER data are imputed. Note: FIBRONEER data represent patients on no background antifibrotics

avalyn

AP01 Activity in AP01-Naïve Cohorts Similar to IPF Patients in ATLAS over 48 weeks




All patients in all cohorts were on 100 mg BID dose throughout


[1] West et al., *Thorax* 2023; 0: 1-8.; [2]Poster Presentation at ATS/RIS 2024

Treatment with 100 mg BID AP01 Showed Favorable Tolerability Profile and Trend Toward Disease Stabilization For Up To Four Years

Cohort 1: ATLAS IPF Patients Rolled Over Into OLE



Cohort 4: AP01-Naïve PPF Patients




- In AP01-naïve PPF cohort, AP01 was well tolerated with safety profile consistent with IPF cohorts
  - TRAEs were cough (10.5%), decreased appetite (7.1%)
  - Only one TEAE of diarrhea and one rash
- At week 48, the mean change from baseline FVC was -31.7 mL

PPF data presented at EULAR 2026, Median duration of therapy 39 months, 28 patients were initially in Cohort 4 with 14 patients ≥ 42 months. IPF data presented at ATS 2025 (Data downloaded October 15, 2024)

avalyn

ATLAS Showed Promising Potential for Disease Modification: Imaging Correlated with FVC Data

Axial HRCT Images



QLF using HRCT imaging after 6 mo treatment with AP01


- **>70% of patients in ATLAS showed stabilization or reversal of fibrosis** on 100 mg BID[1,2]
- Signals of disease course reversal seen, especially with early intervention
- Routine imaging (HRCT) is used to measure and quantify lung fibrosis using AI technology to calculate Quantitative Lung Fibrosis (QLF)
- Data has shown **correlation between lung function (FVC), fibrosis quantification (QLF), and quality of life (QOL)**

Ground Glass (QGG) **Reticulation** (QLF) **Honeycombing** (QHC)

Different types of fibrosis


Kim, H.J.K et al (2026), QLF score in whole lung was 8.5% at baseline and 4.9% at 6-month follow-up. QLF volume in whole lung was 258.2 ml at baseline and 154.2 ml at 6-month follow-up. HRCT; high resolution computed tomography. [1]Poster Presentation at ERS 2024. [2]Poster Presentation at PPF Summit 2023

Stabilization or Reversal of Fibrosis Seen in Majority of Patients on 100mg BID Dose, with Correlation between Lung Function, Fibrosis, and QoL



>70% of Patients Demonstrate Stabilization or Reversal of Fibrosis[1-2]

Correlation between FVC and QLF[3]



Kim, H.J.K et al. (2026)
QLF; quantitative lung fibrosis. [1]Poster Presentation at ERS 2022; [2]Poster Presentation at PPF Summit 2023; [3]West et al., 2023

Modeling of AP01 (nebulized pirfenidone) predicts aerosol distribution throughout the lung




Figure 5. Deposited API mass per central and peripheral region as a fraction of the delivered dose




Figure 6. Deposited API mass per functional category as a fraction of the delivered dose.




Figure 7. Normalized concentration of deposited aerosol mass per mass for healthy vs. fibrotic regions of the lungs.

- Validated[1] *in silico* model for lung deposition
- AP01 lung deposition was evaluated using HRCT models of healthy lungs and lungs from patients with mild and severe IPF.
- Results predict that AP01 is distributed throughout the lung, even in a severely diseased state.

[1]Grill MJ, et al. Commun Med. 2026;6:188. Palacios, M, poster presented at ERS 2026

AP01 is predicted to permeate throughout lung tissue in both healthy and diseased tissue




Figure 4. Transport and deposition of aerosol mass of three cases, visualized in single breath and in slow motion*

*Variation in lung sizes attributed to differences in age, gender, and anthropometrics of the modeled subjects.

Palacios M, et al. In silico modeling of a novel nebulized pirfenidone formulation (AP01) predicts aerosol distribution throughout the lung. Poster #PA4377. Presented at the European Respiratory Society (ERS) Congress 2026, held September 5-9, 2026, in Barcelona, Spain.


Copyright © 2026 by Ebenbuild GmbH and Avalyn Pharma Inc. All rights reserved.

Phase 2b PPF MIST Study is Designed to Support Registration

mist
A PPF CLINICAL STUDY

Patient Population Key Criteria

- PPF patients with recent downward decline in FVC (INBUILD criteria)
- Background SOC allowed:
  - Immunosuppressants
  - Oral nintedanib or nerandomilast (capped at 50%)



- All patients (n=398) will be treated for 52 weeks
- Global study: 150 sites in 14 countries

Primary Endpoint

- Forced vital capacity

Secondary Endpoints


- QoL
- Time to disease progression
- HRCT-based quantitative lung fibrosis imaging

Enrollment completed mid-2026; topline data anticipated 2H 2027

SOC, standard of care; HRCT, high-resolution computed tomography

avalyn

AP01 Program Supported By Over 4 Years of Long-Term Data



ATLAS Open Label Extension Study Complete

- Over 4 years of open label extension data
- Some patients from ATLAS on AP01 for 5+ years

* Patients with IPF (cohort 3) or PPF (cohort 4) who had no other treatment options.

Last updated August 2026. West, A. et al, (2023) *Thorax;* Poster Presentation at ATS 2025. Poster Presentation at EULAR 2026
OLE; open label extension. MIST NCT06329401; SAIL NCT06951217

AP02: Inhaled Nintedanib

avalyn

AP02: Inhaled Nintedanib for the Treatment of IPF Patients

Nonclinical program completed

Phase 1 SAD / MAD trials in healthy volunteers & IPF patients completed, demonstrating:

- 92 healthy volunteers and 6 patients with IPF have participated in Phase 1 studies to date
- PK comparable between IPF patients & healthy volunteers
- Dose-related increase in systemic exposure
- Demonstrates preferential lung exposure with inhalation vs oral administration
- Generally well-tolerated with no bronchospasm or diarrhea observed

Phase 2 underway

First patient dosed in Phase 2 AURA study in 1Q 2026

First AP02 Phase 1 SAD Study (2023) Results Supported Dose Escalation

Phase 1 Study Design


	SAD Cohorts	Lung Exposure Cohorts	IPF Cohort
Cohorts	1-3	4-5	6
Subject	NHVs N=24 6 active, 2 PBO per cohort	NHVs N=8 4 per cohort	IPF N=6
Dose (Single)	0.5, 1.0, 2.0 mg AP02	150 mg oral 2.0 mg AP02	2.0 mg AP02
Measurements	• Safety • Plasma PK • Airway tolerance measures (FEV_1, oximetry, cough)	• Single BAL / ELF timepoint • Safety • Plasma PK • Airway tolerance measures (FEV_1, oximetry, cough) • Estimated ELF PK	• Safety • Plasma PK • Airway tolerance measures (FEV_1, oximetry, cough)

Safety & Tolerability

- ✓ **No** SAEs, bronchospasm or decreased oxygen saturation
- ✓ **All** TEAEs classified as mild; except for 1 moderate headache. All resolved within 48h
- ✓ Tolerability **supported advancement to higher doses**


SAE: serious adverse events; TEAE: treatment-emergent adverse events; BAL: bronchoalveolar lavage; ELF: epithelial lining fluid, Palacios M, et al, *Respiratory Research (2026)*

Second AP02 Phase 1 SAD / MAD Study Design Included Epithelial Lining Fluid Samples



BAL: bronchoalveolar lavage; ELF: epithelial lining fluid, Palacios M, et al, *Respiratory Research (2026)*

AP02 Significantly Improved Nintedanib Lung Exposure



Inhaled at 4mg* vs oral 150 mg

C_{max}

+27x

(2,720 ng/mL vs 99 ng/mL)

$AUC_{0\text{-}24h}$

+27x

*(20,900 ng*h/mL vs 779 ng*h/mL)*

Inhalation improved nintedanib lung exposure vs plasma concentration

Lung exposure, measured as ELF, was evaluated using cross-trial comparative analysis against the ELF data from the first Phase 1 trial of 150 mg nintedanib. The second Phase 1 trial did not include a direct head-to-head comparison of the 4 mg AP02 dose to the approved oral product. A cross-trial comparative analysis against the first Phase 1 study with the same product formulations and patient population criteria was conducted, which may not be reliable as the dosing occurred under two separate protocols.

ELF: epithelial lining fluid ; *n=4 samples/timepoint; C_0 extrapolated; Source: Poster Presented at ATS 2025; Palacios M, et al, *Respiratory Research (2026)*

Inhaled Delivery of AP02 Avoided Systemic Exposure with No TEAEs at 4mg BID

Inhalation Results in Lower Plasma Exposure vs Oral

Inhaled at 4mg vs oral 150 mg

C_{max}	AUC_{0-24h}
-17x	**-26x**
(1.94 ng/mL vs 31.95 ng/mL)	*(14.1 ng*h/mL vs 363 ng*h/mL)*

Generally Well Tolerated

No drug-related AEs at 4 mg BID


No **bronchospasm or cough**

No diarrhea

Poster Presented at ATS 2025, Palacios M, et al, *Respiratory Research (2026)*

avalyn

Inhaled AP02 Concentration Exceeded IC50 For Key Markers of Fibrosis



Select nintedanib *in vitro* kinase inhibition profile[1]

Kinase	IC_{50} (ng/mL)
VEGFR-1	18
VEGFR-2	11
VEGFR-3	7
FGFR-1	37
FGFR-2	20
PDFGR-a	32
PDFGR-b	35

Precision cut lung slice (PCLS) model system uses IPF patient derived tissue explants to assess biomarker response.

PCLS, precision cut lung slice; ELF, epithelial lining fluid. [1]Roth, 2014, et al. Journal of Medicinal Chemistry.

Now Enrolling: AP02 Phase 2 AURA IPF Study Design

AURA-IPF
AN IPF CLINICAL STUDY

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial Evaluating the Safety and Efficacy of AP02 in IPF

Patient Population Key Criteria

- Male or female ≥40 years
- Patients with IPF not actively on background antifibrotics
  - Patients may have been on oral nintedanib, pirfenidone, or nerandomilast previously but were intolerant to orals



- All patients (n=160) will be treated for 12 weeks
- Subjects will have 1 week of open-label nebulized saline to establish a baseline for cough

Primary Endpoint

- Change from baseline FVC over 12 weeks

Secondary Endpoints

- Change from baseline quantitative analysis on HRCT
- Time to disease progression

Enrollment initiated 1Q 2026; topline data anticipated late 2027

avalyn

AP03: Fixed Dose Combination

avalyn

AP03 Fixed Dose Combination: The Next Step in Portfolio Expansion

Healthy volunteers

- SAD cohort
- 7-day MAD cohort

Initial dosing

- 50 mg pirfenidone + 2 mg nintedanib
- Opportunity to dose escalate

Endpoints

- Safety and tolerability
- Pharmacokinetics of inhaled pirfenidone and nintedanib


Phase 1 study initiated in **4Q26** with results anticipated **2H27**

SAD, single ascending dose; MAD, multiple ascending dose


SAD: single ascending dose; MAD multiple ascending dose. ACTRN 12626001341314.

AP03 Informed by Third Party INJOURNEY Trial That Showed Improved Efficacy in Combination with Significant Tolerability Challenges

Increased Efficacy Benefit with Combination at 12Wks



Worse Tolerability with Combination of Oral Agents



Vancheri et al., 2017

avalyn



For patients like Peter…

He was first treated in our ATLAS study in 2020 and remains on treatment in our open-label extension today, over five years later.

avalyn

We wake up every day to improve the lives of patients.

Avalyn Strategy:
Innovation With The Goal Of Improving Patient Outcomes In Rare Lung Diseases

Large patient base with **high unmet need**

New formulation of approved **medicines** with derisked mechanism of action

Device selection that offers medical and commercial advantages

Multiple near-term clinical catalysts anticipated in 2H 2027

avalyn